Positive judgement on the international patent application for Temodex
Double Bond Pharmaceutical AB has now received a positive judgement on a comprehensive review of the international patent application for Temodex – the novel therapy against brain cancer. The European Patent Office (EPO) was selected as the Examining Authority to get a critical and detailed analysis on how the application will be reviewed and evaluated by EPO in the European phase. The international patent application (PCT) for Temodex was submitted by Double Bond Pharmaceutical on April 28th 2017.
"It is extremely important for Double Bond Pharmaceutical that EPO considers our patent application to meet patentability requirements", - commented CEO Igor Lokot. "This message is fully in line with our plan and is a very important milestone in both short- and long-term development of Temodex."
Temodex, which is a locally acting formulation of temozolomide, was developed by RI PCP in Minsk, Belarus, and is registered for marketing within Belarus since 2014 as the first-line treatment of glioblastoma. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. Find out more here.
About the company: www.doublebp.com
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14th of August 2017.
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. DBP acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015. The company was granted Orphan Drug Designation status by EMA for Temodex in July 2016.